The US Bankruptcy Court gave an order approving the sale of substantially all the assets of DMK Pharmaceuticals Corporation on May 8, 2024. The debtor has been authorized to sell substantially all its assets to Zmi Management Inc for a purchase price of $3.17 million in cash. David R. Eastlake and Hans E. Biebl of Greenberg Traurig, LLP acted as legal advisors to the buyer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.03 USD | -25.00% | -.--% | -95.72% |
May. 30 | First Motion for Exclusivity Period Extension Filed by DMK Pharmaceuticals Corporation | CI |
May. 08 | Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation | CI |
1st Jan change | Capi. | |
---|---|---|
-95.72% | 303K | |
+40.73% | 739B | |
+31.60% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.47% | 240B | |
+9.50% | 210B | |
-5.32% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- DMKPQ Stock
- News DMK Pharmaceuticals Corporation
- Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation